HELSINKI – January 17th, 2024 – In a strategic move to strengthen its market leadership, Finnish health technology pioneer CurifyLabs, announces its acquisition of significant intellectual property (IP) from Mehta Heino Industries Oy, a front-runner in 3D printing hardware development. The acquisition marks a pivotal moment in CurifyLabs' capability to offer unparalleled 3D printing solutions for producing personalized medicines in the pharma industry.
Charlotta Topelius, co-founder and CEO of CurifyLabs, said: "The acquisition of Mehta Heino's IP and other assets is a game-changer for us. Their innovative approach to 3D printing technology perfectly aligns with our vision enabling wider adoption of personalized treatments. This acquisition is not merely about growing our portfolio; it's about leading the industry into a new era."
In addition to the IP acquisition Petri Heino, CTO of Mehta Heino joins CurifyLabs as Lead Hardware Engineer, further strengthening CurifyLabs’ position in redefining the landscape of solutions in personalized medicine manufacture.
Petri Heino commented: "CurifyLabs presents an extraordinary opportunity to push the boundaries of what is possible in 3D printing and advanced robotics in healthcare. Me and my Co-Founder Santosh Mehta spent eight years developing our technology and we are thrilled to see our IP contribute to groundbreaking advancements for the benefit of vulnerable patient populations that need personalized treatments.”
Commitment to Advanced Automation and Robotics
CurifyLabs' Pharma Kit solution, combining innovative printable Pharma Inks with 3D printing technology and quality control, provides an automated solution for producing personalized medicine in hospitals and compounding pharmacies. The solution eliminates the manual process and makes compounding more accessible, cost-effective, safe, and scalable. CurifyLabs is bringing automation to pharmacy compounding and with this acquisition new features are made possible.
Niklas Sandler, Co-founder and CTO at CurifyLabs, stressed the importance of regulatory compliance and speed: "For pharmacies, speed, seamless workflows, and regulatory compliance are essential. We enable this with our unique personalized medicine manufacturing solution. With Mehta Heino's IP, we're taking our commitment to effective solutions to the next level. Our combined expertise will result in more efficient manufacturing solutions, facilitating the wider adoption of personalized medicine and enhanced care for patients with individual needs.”
The demand for personalized medicine is increasing. Uniformed drug treatments often fall short of addressing the unique needs of patients. Personalized treatment and medication are crucial, especially for cancer patients and children. According to a report by the European Commission, currently, over 50% of medicines are not registered for use in children. CurifyLabs continues to focus product development especially on pediatric populations.
Topelius emphasized, "We must pay special attention to pediatric populations where personalized medicines are crucial. The IP acquisition and adding Petri to our team enhance our ability to do just that."
About CurifyLabs
CurifyLabs is a Finnish healthtech company developing solutions for producing personalized medicines in hospitals and compounding pharmacies. CurifyLabs' automated on-demand manufacturing concept, “the Pharma Kit” and printable pharmaceutical inks, enable personalized mass customisation of medicines, allowing patient safety and efficacy at a significantly lower cost. CurifyLabs was founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius. The patented solution is based on over a decade of academic research by Niklas Sandler. CurifyLabs has customers in eight European countries and employs a team of 20 professionals.
Curifylabs.com